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Abstract
Tuberculosis (TB) is a curable and preventable disease; however, in 2015, 10.4 million
people were diagnosed with TB, making it one of the top 10 causes of mortality. A major
part of the TB disease burden is carried by low and middle-income countries. In Ethiopia,
which ranks 15th among 22 countries with a high burden of TB and multidrug resistant
TB (MDR-TB), important diagnostic and treatment gaps persist. This quantitative
descriptive study was primarily aimed to determine levels of adherence to standardized
TB laboratory procedures by calculating and reporting the number of sputum samples,
and reporting valid and documented results of laboratory Ziehl Neelsen (ZN) stain tests
and MDR-TB tests for each suspected TB patient at a community health center TB
laboratory in Addis Ababa, Ethiopia. The social theory of unanticipated consequences for
purposive or social action was the theoretical framework for this study. Study results
revealed that the optimal number of 3 samples sputum specimens collected for each
suspected TB patient was submitted only for 48.1% of the study population. Also,
regarding the percentage of valid and documented results for the 3 samples when
performing laboratory ZN stain tests, for each suspected TB patient, there were valid
results only for 72.2%, 51.2%, and 47.5% of the study participants, respectively. Finally,
the percentage of valid and documented results when performing the MDR-TB test for
each suspected TB patient was only 13.6%. For all the data, WHO criteria for
error/undocumented results were not met. The study will contribute to changing the way
Ethiopian laboratory technicians and managers address local challenges involving TB
assessment, resulting in a positive social change in TB diagnosis and treatment.
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1
Section 1: Foundation of the Study and Literature Review
Introduction
The genus Mycobacterium originated more than 150 million years ago . The
organism Mycobacterium tuberculosis causes tuberculosis (TB). TB is a communicable
disease (World Health Organization [WHO], 2019). The disease is spread from person to
person through the air; when people with lung TB cough, sneeze, or spit, they propel the
TB germs into the air. A person needs to inhale only a few of these germs to become
infected. People infected with TB bacteria have a 5-15% lifetime risk of falling ill with
TB. However, persons with compromised immune systems, such as people living with
HIV, malnutrition, or diabetes, or people who use tobacco, have a much higher risk of
falling ill (WHO, 2018). Undiagnosed and thus untreated Mycobacterium tuberculosis
infection is deadly and if undiagnosed and untreated it leaves the country’s population
vulnerable to spreading the bacteria to families and to community members.
TB disease is a curable and preventable disease; however, in 2015, 10.4 million
people were diagnosed with TB, making it one of the top 10 causes of death, with a death
toll of 1.4 million worldwide (WHO, 2017b). Even though many steps have been taken to
eradicate the disease, in 2015, TB was still one of the top 10 killers globally, ranking
above HIV/AIDS as a leading cause of death from infectious disease (WHO, 2016a).
A major part of the TB disease burden is carried by low and middle-income
countries (LMIC), as TB is a disease of the poor. Houben et al. (2016) said that the high
burden of TB disease in LMICS requires even more accelerated TB prevention programs
consistent with available resources in these countries to have a direct impact on case

2
identification, diagnosis, and treatment with the hopeful result of saving lives. Detection
of the organism is achieved through laboratory procedures that can be simple manual
procedures or expensive and highly technical automated procedures.
TB disease is a debilitating disease and treatment can only be initiated after
detection of the organism causing the infection. Therefore, accurate and timely diagnosis
followed by access to immediate treatment will save lives and resources. This can only be
achieved through social change that empowers local level laboratory professionals and
managers to own the process and initiate and sustain laboratory methodologies that
consider local resources.
The rise of multidrug-resistant TB (MDR-TB) and extensively-drug resistant TB
(XDR-TB) infection have created more challenges for health professionals as they
continue to eradicate infections. MDR-TB is TB infection that does not respond to at
least isoniazid and rifampicin, the two most powerful anti-TB drugs (WHO, 2017c).
XDR-TB is a form of MDR-TB with additional resistance to more anti-TB drugs that
therefore responds to even fewer available medicines. It has been reported in 117
countries worldwide (WHO, 2017c).
MDR-TB and XDR-TB continue to emerge because of the mismanagement of TB
treatment and person-to-person transmission of MDR-TB infections. Most people with
TB are cured by strictly following a 6-month drug regimen, but inappropriate or incorrect
use of antimicrobial drugs or use of ineffective formulations of drugs (such as single
drugs, poor quality medicines, or unacceptable storage conditions), and premature
treatment interruption can cause drug resistance, which can then be transmitted,
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especially in crowded settings such as prisons and hospitals (WHO, 2018). In some
countries, it is becoming increasingly difficult to treat MDR-TB. Treatment options are
limited and expensive. At $1000 U.S. dollars per patient, the new treatment regimen can
be completed in 9-12 months and recommended medicines are not always available, and
patients experience many adverse effects from the drugs.
The WHO (2016a) reported that the equivalent of $6.6 billion U.S. dollars was
available for TB prevention, diagnosis, and treatment in low- and middle-income
countries in 2016. They based their determination on data reported to the WHO for 126
countries with 97% of the world’s notified TB cases. This amount in 2016 was an
increase from previous years, but was still about $2 billion U.S. dollars less than the
estimated requirement for this group of countries. The Who (2016a) stressed the need for
$2 billion U.S. dollars and more commitment from local and international agencies.
The target to end global TB is reflected in the WHO’s Sustainable Development
Goals (SDG). The SDGs were adopted by the United Nations (UN) in September 2015
and covers the period 2016 to 2030. The End TB Strategy has a 20-year timeframe
(20162035) and was unanimously endorsed by the WHO’s member states at the 2014
World Health Assembly. Targets set for the End TB Strategy included a 90% reduction in
TB deaths and 80% reduction in TB incidence by 2030, as compared to 2015 (WHO,
2016a).
Ethiopia is one of the world’s oldest civilizations and one of the world’s poorest
countries (World Bank, 2017). It is the second-most populous country in Sub-Saharan
Africa with a population of 99.4 million, and a population growth rate of 2.5% in 2015.
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Poverty and dense population lead to a higher rate of transmission of communicable
diseases, including TB. Ethiopia ranks 15 among the 22 countries with a high burden of
TB and MDR-TB. In Ethiopia, the annual HIV-negative TB mortality and HIV-positive
TB mortality is estimated to be 15,000 to 38,000 deaths and 1,600 to 7,300 deaths,
respectively. Globally, 22 countries are considered to have a high burden of TB and
MDR-TB and Ethiopia ranks 15 among these countries. Table 1 shows estimated TB
burden in Ethiopia.
Table 1
TB Disease Burden in Ethiopia 2014

Number (thousands)
Mortality (excludes HIV+TB)
Mortality (HIV+TB only)

Rate per 100,000 population

32 (22-43)

33 (23-44)

5.5 (4-4-6.8)

5.7 (4.6-7)

Prevalence (includes HIV+TB)

190 (160-240)

200 (161-243)

Incidence (includes HIV+TB)

200 (160-240)

207(168-250)

Incidence (HIV+TB only)

19 (15-23)

Case detection, all forms (%)

60 (49-73)

19 (15-24)

The Federal Ministry of Health (FMOH, 2015) reported that important
diagnostic and treatment gaps persist and listed the irregular supply of laboratory reagents
as one of the top challenges. From 2014 to 2015, the TB case detection rate (number of
cases notified divided by the number of cases estimated for that year) in Ethiopia was
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67.3%, which was below the 83.0% target set by the WHO for the same year. Reves and
Angelo (2016) noted that a major impediment to achieving the End TB Strategy in
Ethiopia is the low TB case detection rate, which was 60% in 2015. Reves and Angelo
said that 25% of the estimated 2,200 MDR-TB patients were identified. Therefore, it is
important to increase the detection rate of TB and MDR-TB in Ethiopia.
Reviewing laboratory procedures may provide a better understanding of the
challenges public health officials face when seeking to improve TB and MDR-TB
detection rates in Ethiopia. To aid in this endeavor, this doctoral study assessed daily TB
laboratory procedures at Community Health Center TB Laboratory in Addis Ababa from
August 1, 2015 to December 31, 2016.
In this section, the problem statement, purpose, research questions, theoretical
framework, literature review regarding concepts under study, assumptions, definitions,
and scope and delimitations will be discussed.
Problem Statement
There is a problem regarding delay and accurate diagnosis and treatment for TB
patients. Houben et al. (2016) said that the high burden of TB disease in LMICs requires
even more accelerated TB diagnosis tools and prevention programs. Ethiopia is one of the
high burden countries (HBCs), and it will be the focus of my proposed research.
Improving the low TB case detection rate is a challenge that Ethiopia faces, as the
country is moving to achieve End TB Strategy objectives by 2035. The WHO (2016a)
reported that the rate of decline in TB incidence was as low as 1.5% from 2014 to 2015,
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which is a much lower annual rate compared to the 4.5% yearly rate of decline needed by
2020 to meet the 2030 TB objective.
Another area of concern when considering how to enhance TB prevention is a
delay in diagnosis. Although, there are regional variations for the delay in TB diagnosis
and treatment, Bogale, et al. (2017) stated in Northwestern Ethiopia, it generally ranges
from 40–97 days. Many factors cause a delay in diagnosis and treatment, but it is mainly
related to health care seeking behavior, health system delivery, and timely diagnosis and
treatment (Bogale et al. 2017).
There are various procedures to diagnose TB. A direct sputum smear examination
using Ziehl Neelsen (ZN) staining is the most commonly-used procedure in many lowincome counties, including Ethiopia. The method is low-priced, but its low sensitivity is a
problem (Kivihya-Ndugga, van Cleeff, Juma, & Kimwomi, 2004). Depending on the
number of specimens examined, ZN detects 30- 60% of culture-positive TB suspects.
Moreover, a collection of sputum samples on three consecutive days is required, which is
burdensome for patients and makes compliance difficult. Therefore, this might delay
diagnosis and treatment. Polymerase chain reaction (PCR) techniques have higher
sensitivity and specificity than conventional smear examination with ZN stain. However,
the presence of a reliable support system that includes training and timely technical
backing is highly recommended to make the PCR testing worthwhile. Among culturepositive patients, a single direct MTB/RIF test identified 551 of 561 patients with smearpositive tuberculosis (98.2%) and 124 of 171 with smear-negative tuberculosis (72.5%).
Testing three samples increased the sensitivity to 90.2% (Sujata, 2014). It is important to
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investigate that diagnostic tools are accurate, adhere to WHO standards, and are
supported by available resources in the local area to have a direct impact on case
prevention and saving lives.
Purpose of the Study
This quantitative descriptive study primarily aimed to determine levels of
adherence to standardized TB laboratory procedures by calculating and reporting the
number of sputum samples from each suspected TB patient, and the valid/documented
results of laboratory ZN stain test and MDR-TB test for each suspected TB patient at a
Community Health Center TB laboratory in Addis Ababa, Ethiopia. Second, I compared
these data to similar data reported by the WHO and other countries to ascertain how
Ethiopia stands regarding these standardized procedures.
There are significant inequalities that exist among and between countries in terms
of their ability to access TB diagnostic and treatment. Of the estimated 9.6 million people
who fell ill with TB globally in 2014, 6 million (62.5%) were reported to national
authorities (WHO, 2015). Worldwide, 37.5% of TB cases went undiagnosed or were not
reported to local governments/health authorities, posing a high risk of transmission to
communities. TB diagnosis and treatment is an essential part of any country’s health
delivery system, and there are multiple factors contributing to delays in diagnosis and low
case detection rates. The proposed research explored laboratory procedural capabilities
and limitations in a community health center TB laboratory in Addis Ababa, a major
urban city in Ethiopia.
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From 2015 to 2016, the laboratory at a community health center TB laboratory
in Addis Ababa used the ZN acid-fast bacilli (AFB) stain procedure to determine the
presence and absence of tuberculosis bacteria in sputum samples. Also, the community
health center used a Gene- Xpert PCR instrument to determine the presence and absence
of MTB and to determine if the organism is resistant to rifampin. The device is endorsed
for use in resource-limited settings. Rifampin is one of the first-line antibiotics used to
treat TB infection; therefore, determining if TB organisms are resistant to rifampin
enables clinicians to adjust medication and help TB infection control programs stop the
spread of rifampin-resistant TB in the community.
The ZN AFB stain procedure requires three sputum samples from patients
suspected to have TB infection. There are several steps that the laboratory is required to
follow to produce reliable laboratory results. The procedural steps that the Community
Health Center TB laboratory in Addis Ababa use and the WHO laboratory manual will be
described in detail. Daily activities of the laboratory will be obtained from secondary
data. Data will include the number of sputum samples collected, number of ZN stain
performed, the number of ZN stain results documented, results of Gene Xpert PCR tests
documented, and number of laboratory test results errors, invalid results, and no result
documentation. The study analyzed any undocumented laboratory results, error codes,
and invalid laboratory results as a measure of the level of the laboratory’s procedural
capabilities and limitations.
Research Questions
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RQ1: During the period between August 1, 2015 and December 31, 2016 at a
community health center TB laboratory in Addis Ababa, what was the number of sputum
samples for detection of mycobacterium tuberculosis for suspected TB patients?
RQ2: Between August 1, 2015 and December 31, 2016 at a community health
center TB laboratory in Addis Ababa, what was the percentage of valid/documented
results when performing the laboratory ZN stain test for suspected TB patients?
RQ3: During the period between August 1, 2015 and December 31, 2016 at a
community health center TB laboratory in Addis Ababa, what was the percentage of
valid/documented results when performing laboratory MDR-TB tests for suspected TB
patients?
Theoretical Foundation of the Study
Global health issues involve unique social dynamics that set them apart from all
other social phenomena. Kleinman (2010) stated that global health is often viewed as a
collection of health problems rather than a science discipline. However, the social theory
of unanticipated consequences for purposive (or social) action can help understand
challenges Ethiopia is facing in fighting TB. Sociologist Robert Merton first introduced
the theory in 1936. Merton (1936) said one acts rationally by selecting means based on
the available evidence, and yet the health goal may not be attained. Unorganized action
refers to acts of individuals, and the formally organized action refers to like-minded
individuals who form an association to achieve a common purpose. Unanticipated
consequences may follow both types of action. Merton was interested in consequence of
community/sate organized action, not organized efforts of individuals (De Zwart, 2015).
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Limited knowledge can be the sole barrier to correctly anticipating a future
outcome. Solinas-Saunders and Stacer (2015) said that some health interventions result in
unintended consequences that are unpredictable while some are seen and prevented. One
example is the unintended consequence of China’s one-child per family population
control policy, which gave birth to a sexual revolution in China (Kleinman, 2010).
Merton’s theory of unintended consequences of social action is useful to
investigate how decision-makers decide what is beneficial for a local area. But SolinasSaunders and Stacer (2015) noted that many factors are intertwined and choices are
formed within a social context constrained by time and space. One’s action rationality is
a function of their interpretation of reality in the context of a social system (Merton,
1936). Rationality is not synonymous with objectivity. Rationality is subjective since it
is determined by human actions within the boundaries of an existing social structure
(Solinas-Saunders & Stacer, 2015). Based on Merton’s theory of unintended consequence
of purposive action, the demand for social engagement is pressing, as is the need for
immediate results.
According to Merton (1936), available knowledge is another way in which
decision-makers’ conclusions are restrained. When trying to decide what type of
treatment, diagnostic procedures, or medical equipment is appropriate, decision-makers
need information about local resources, culture, practices, needs, and wants of the local
area. Solinas-Saunders and Stacer (2015) said acquiring sufficient knowledge takes
energy and time, that actors including local health professionals and international
agencies may not have. There is a need for immediate results or imperious immediacy of
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interest. Consequently, decision-makers are limited in their ability to anticipate
consequences of purposive actions correctly. They lack knowledge or the ability to
translate knowledge into empirical data with the need to obtain immediate results limits
the ability to predict results with certainty (Merton, 1936). Therefore, the proposed study
assessed day-to-day laboratory activities to understand challenges and limitations that
were not apparent at the time of decision making. The issue of Ethiopia’s limited
infrastructure, insufficient technical training, and limited troubleshooting abilities of
laboratorians need to be considered in full before making any decisions. It is also crucial
to investigate infrastructure capabilities, training, and technical support. These activities
should be determined, sustained, and managed by the country’s local health department
managers with total backing from decision-makers and international agencies.
Nature of the Study
The study encompassed descriptive quantitative analysis of secondary data from
August 1, 2015 to December 31, 2016 obtained from a community health laboratory in
Addis Ababa, Ethiopia. The variables under study are number of specimens collected, TB
microscopic test results, and MDR-TB test results using the Gene Xpert instrument, as
indicated in laboratory records.
The WHO (2013) indicated that three consecutive sputum microscopies can
identify 95- 98% smear-positive samples. The WHO (2013) said to collect the first
specimen, early morning at home. The second sample should be collected when the
patient presents to the laboratory on visit #1 and bring the third specimen the following
day (visit #2). Alternatively, microscopic examination of two consecutive sputum
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specimens collected on the same day may be performed. The minimum expectation the
WHO set for HBCs is 90%. Analysis of laboratory functions will determine what the
laboratory currently is doing and should be doing based upon WHO recommendations.
The study involved data obtained from a community h/ealth center using descriptive
statistics to understand gaps and successes of the laboratory procedural steps. Data
analysis included data from the collection of three sputum specimens, results of sputum
smear microscopic tests, and results of Gene Xpert PCR tests during August 1, 2015 to
December 31, 2016. Secondary data for this study did not include patients’ treatment
information. Therefore, the study did not examine associations between laboratory patient
results and treatment success or failure.
Literature Search and Strategy
The literature review is central to the research study. A literature review provides
the foundation for research by including those articles that highlight the importance of the
research questions. After formulating research questions, researchers move to understand
what studies have been done and conclusions have been reached involving the research
questions. During the literature review, reviewers seek to synthesize published research
findings that relate to the research questions. It is also essential that reviewers evaluate
literature for applicability, thoroughness, and significance as they apply to research
questions. A necessary part of the literature review includes health information data, and
population surveys conducted by local or international organizations.
I used CINAHL, MEDLINE, and Thoreau to access many full-text and peerreviewed articles. I also used the websites of the WHO, Centers for Disease Control and
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Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID),
Tuberculosis Research Advisory Committee (TRAC), and the FMOH. I reviewed annual
reports and articles related to MTB infections, diagnosis, and treatment. Search terms
used were: Mycobacterium tuberculosis, high burden countries, MTB diagnosis, TB in
Ethiopia, TB laboratory in Addis Ababa, TB laboratory, GeneXpert instrument, MDR-TB
and TB case detection rate, TB microscopic, laboratory procedures, and TB in SubSharan Africa.
Literature and journals reviewed include articles published between 2009 and
2017. The journal articles I reviewed addressed burdens of TB and TB diagnosis in
Ethiopia extensively. Other topics of interest were poverty, access to healthcare,
laboratory management, TB laboratory procedures in Ethiopia, and laboratory
management systems in other LMICs.
Literature Review
Addis, Birhan, Derseh, Sahle, and Gizaw. (2013) said that a considerable
contributor to the root cause of dissatisfaction for Ethiopian healthcare professionals is
poor quality of laboratory support. Haile, Mesfin, McNerney, and Gezehegn. (2014) said
a major challenge for Ethiopian laboratories is to get continued commitments from
managers and administrators to maintain laboratory excellence. Shortage of reagents and
other consumable materials, including quality control materials, and lack of adequate
resources for training laboratory personnel is a countrywide problem in Ethiopia.
Countries with limited resources do not need to adapt to recent technologies
beyond their reach. Many highly technologically-advanced methodologies require initial
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training, the ability to troubleshoot and correct instrument error messages, daily quality
control and preventative maintenance of instruments, and ongoing competency
verification. Sinishaw, Gebregorgis, and Shiferaw (2015) researched 82 health centers in
the Amahara region in Ethiopia, and found that 40.2% of the health centers were
understocked in terms of at least one reagent that is required to diagnose TB infection.
Moreover, 93% of the 82 health centers did not fulfill the standard for effective
distribution of laboratory supplies (Sinishaw et al., 2015). Reagents, supplies, and
technical assistance are out of reach for some laboratories, which causes delays of test
results or can produce incorrect results. Such delay defeats the purpose of engaging in the
use of advanced technology. Ridderhof, Deun, Kam, Narayan, and Azize (2007) said that
TB laboratories could either serve as a vehicle for progress or can inhibit further progress
in TB control.
About half of the medical equipment in developing countries are poorly
maintained; therefore, they are often out of order (Fonjungoa et al. 2012). Manalebh,
Demissie, Mekonnen, and Abera (2015) conducted a cross-sectional study to evaluate
sputum smear microscopy in 37 public-private mix (PPM) laboratories in the Western
Region, Ethiopia. Manalebh et al. (2015) employed onsite evaluation and blind
rechecking, and 67.6% of PPM-DOTS laboratories were found to be below standard
recommended physical space. The quality of AFB staining reagents were also found to be
substandard in private DOTS laboratories. These led to poor quality of sputum smear
microscopy, and internal quality control was not regularly practiced. Sinishaw et al.
(2015) found 7% of laboratories in Ethiopia’s Amhara region use poor quality specimens.
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Smear thickness and evenness were not acceptable in 66.2% and 62.7% of laboratories,
respectively. The study also confirmed an inefficient supply distribution system which
left many health centers with no or low stocks of TB reagents and supplies. Reagents and
supplies are also central to quality assurance processes. Decentralized quality assurance
processes improve TB microscopic test results. Melese et al. (2016) said external quality
assurance (EQA) processes were expanded from four regional laboratories to 82 EQA
centers, which included 956 health facilities (HFs). The EQA process involved
rechecking AFB smears for false negatives (FN) and false positives (FP). The EQA
process led by the Ethiopian Public Health Institute (EPHI) and funded and supported by
the CDC was the gold standard. Training and mentoring laboratory professionals and
instituting internal quality assurance (IQA) occurred during the period between 2012 and
2014 and the FP rate declined from 0.6% to 0.2%, and the FN fell from 7.6% to 1.6%.
Melese et al. (2016) said that direct sputum microscopy for AFB using light microscopy
is a test predominantly used to detect bacteria worldwide. The test is cost-effective, easy
to train people to perform, and does not require a sophisticated instrument. But sputum
microscopy for AFB heavily relies on external and internal QA, continuous quality
improvement programs, and a reliable source of reagents.
Fonjungoa et al. (2012) said that laboratories should follow standard operating
procedures with functioning equipment to obtain reliable and reproducible results that
maintain turnaround time. Birhanaselassie (2015) said that laboratory service facilities
and health facilities in Ethiopia have been reported to be very weak and limited.
Birhanaselassie (2015) also identified many areas of concern, including lack of close
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follow-up and supervision by hospital managers and governmental health agencies. These
gaps are directly linked to ineffective laboratory processes. Clinical laboratories are an
essential part of the healthcare system. Failed laboratory management systems can lead to
unreliable diagnostic methodologies and inappropriate treatment, which can lead to
increased morbidity and mortality (Birhanaselassie, 2015). Often, LMIC laboratories
receive highly sophisticated laboratory instruments such as the Gene Xpert instrument at
a reduced price. However, they usually have limited power to negotiate for low-cost
consumables and employee training, so potential improvements in laboratory capabilities
are often not realized.
The two most commonly-used microscopic procedures to recover TB organisms
from a sputum sample are conventional ZN microscopy and fluorescence microscopy.
Fluorescence microscopy is more sensitive (10%) and takes less time (WHO, 2011).
However, it requires expensive mercury vapor light sources with regular maintenance and
a dark room, which makes it inaccessible in most resource-limited countries. The WHO
(2011) said LED microscopy was developed mainly to give resource-limited countries
access to the benefits of fluorescence microscopy. LED microscopes are available in
Ethiopia; they are less expensive, require less power, and can run on batteries.
As part of SDGs to end the global TB epidemic by 2030, the Strategic and
Technical Advisory Group for Tuberculosis (STAG-TB) provides technical guidance to
the WHO. The STAG-TB provides objective, ongoing technical, and strategic advice to
the WHO related to TB care and control. The WHO (2016d) supported the inclusion of
patients and affected communities to enable their voice to inform policymaking and
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program planning at every level. The literature review indicates shortages of laboratory
consumables and lack of close follow-up and supervision from managers and
governmental health agencies leads to incomplete and delayed laboratory results. The
proposed study will reiterate the importance of engaging local laboratory professionals
and managers and empowering them to own laboratory support processes. Highly
advanced technology might not always be fitting. The study can encourage and educate
Ethiopian laboratorians and managers to consider local resources before adapting TB
laboratory methods. Building confidence in laboratory managers to be decision-makers in
their local area will lead to positive social change.
Haile et al. (2014) said that the level of commitment among laboratory managers
in Ethiopia varies and affects the continuity of good laboratory practice. Haile et al.
(2014) said that there is a country-wide problem regarding purchasing of reagents,
laboratory consumables, and quality control materials.
Addis et al. (2013) said that 86.7% of physicians and nurses in Ethiopia have
encountered lost laboratory reports. Loss of laboratory results were not directly
associated with the healthcare provider’s level of dissatisfaction. However, it represents a
possible compromise in providing timely treatment to patients.
Mala, Moser, Dinant, and Spigt (2014) conducted a study in Tigray, Ethiopia to
understand why TB service providers in Ethiopia do not follow treatment guidelines.
Thirty-nine TB care providers participated in a focus group discussion. Healthcare
providers developed negative expectations about the results of sputum smear microscopy
tests. There are three main reasons for noncompliance of TB treatment guidelines. The
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first is Ethiopia’s limited ability to correctly diagnose TB and give the right treatment.
Second is the lack of clarity of local guides with recommendations when to retest those
patients whose initial tests are negative. Third is the lack of complete diagnosis and
treatment documentation. Also, there are five factors that influence noncompliance
among TB care providers: insufficient diagnostic modalities, ambiguity in guidelines and
recommendations, poor patient care documentation, state of healthcare services, and
healthcare providers in government-run or private hospitals showing little interest in
following national guidelines.
Fiseha and Demissie (2015) emphasized the importance of decentralized TB
treatment centers in Ethiopia. Patients are not able to comply with direct observation
treatment (DOT) because treatment centers congregate in the city, away from the rural
community. Moreover, enhanced severity of the disease when co-infection with HIV
reduces adherence. The study also gives insights about factors that influence TB
treatment adherence. One is the patient’s belief about the curability of TB disease.
Second is support from family, friends, the community, and health professionals, all of
whom can help the patient to seek treatment and adhere to the medication regimen.
Temesgen and Demissie (2014) conducted a study in the Amhara region in
northwestern Ethiopia to assess the knowledge and practice of M. tuberculosis infection
control (TBIC). The study involved 313 healthcare providers in four hospitals. In the
study, TBIC knowledge and practice were used as dependent variables. Independent
variables establishing TBIC knowledge and practice were sociodemographic
characteristics, years of service, level of education, professional categories, job location,
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and training regarding TBIC. Knowledge about TBIC was a strong predictor of good
TBIC practice. Only 18% of participants were trained on TBIC. Years of service or level
of education was not associated with TBIC knowledge. Even though there was a high
prevalence of TB with a high probability of TB nosocomial transmission, most health
facilities in Ethiopia do not have TBIC practices. Therefore, patients and providers are at
risk of exposure to TB, especially at high caseload facilities.
Fiseha and Demissie (2015) found that healthcare workers (HCWs) shared their
concern about contracting TB/MDR-TB due to the absence of standard TB IC measures.
Given the high cost of infection control processes, most low-income countries cannot
afford to implement them.
Kivihya-Ndugga et al. (2004) discussed Nairobi, Kenya, where sputum
specimens from 1, 396 TB suspected patients were analyzed for the presence of TB using
the PCR assay. The result showed a sensitivity and specificity at 93% and 84%,
respectively. The concern is the cost-effectiveness and operational effectiveness for lowincome countries with high-burden of TB.
Scherer et al. (2004) said when using culture as a gold standard, a sensitivity
ranges from 77% to more than 95%. However, for smear-negative specimens, PCR
sensitivity has been reported to be below 90%. Scherer et al. (2004) also examined
sensitivity for HIV positive versus HIV negative patients, showing lower sensitivity for
HIV positive patients.
Definitions
Definitions of terms used in the study are as follows:
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Acid-fast bacilli (AFB): is a type of bacteria that causes tuberculosis and certain
other infections (WHO, 2010).
Colour test: A simplified and more timely TB culture method when compared
with traditional culture methods. It was designed to assist with more timely confirmation
of TB infections, particularly in low resource settings. The colour test combines the thinlayer agar technique with a simple colour-coded quadrant format, selective medium to
reduce contamination and colorimetric indication of bacterial growth to simplify
interpretation. DST patterns for isoniazid (INH), rifampicin (RMP), and ciprofloxacin
(CFX) were determined using the Colour Test for 201 archived Mycobacterium
tuberculosis isolates.
Extensively-Drug Resistant Tuberculosis (XDR-TB): A form of multidrugresistant TB with additional resistance to more anti-TB drugs that therefore responds to
even fewer available medicines. It has been reported in 117 countries worldwide (WHO,
2017c).Xpert MTB/RIF Assay: A qualitative, nested real-time PCR in vitro diagnostic test
for the detection of TB complex DNA in raw sputum. In specimens where MTBcomplex is detected, the Xpert MTB/RIF assay also detects rifampin-resistance
associated with mutations of the rpoB gene (WHO, 2017c).
Latent TB Infection: TB bacteria can live in the body without making a person
sick. In most people who breathe in TB bacteria and become infected, the body can fight
the bacteria to stop them from growing. Latent TB infections can activate to become TB
(CDC, 2017).
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Multi-Drug Resistant Tuberculosis (MDR-TB): The bacteria that cause TB can
develop resistance to the antimicrobial drugs used to cure the disease. MDR-TB is TB
that does not respond to at least isoniazid and rifampicin, the two most powerful anti-TB
drugs (WHO, 2017c).
TB-LAMP: A manual assay that requires less than one hour to perform and can be
read with the naked eye under ultra violet light. The WHO (2016c) recommended that the
TB-LAMP can be used as a replacement for microscopy for the diagnosis of pulmonary
TB in adults with signs and symptoms of TB.
Xpert MTB/RIF: An automated, cartridge-based nucleic amplification assay for
the simultaneous detection of TB and rifampicin resistance directly from sputum which
takes less than 2 hours (WHO, 2017a).
Ziehl-Neelsen (ZN) Stain: A smear prepared directly from sputum specimens and
it is the most widely available test for diagnosis of TB in resource-limited settings. ZN
microscopy is highly specific, but its sensitivity is variable (20-80%) and is significantly
reduced in patients with extrapulmonary TB or HIV (WHO, 2010).
Assumptions
According to the WHO (2017b), there is a global caution practiced when using
country health information system (HIS), including vital registration because of concerns
with information/data quality and completeness. The WHO emphasized the need to
strengthen each country’s HIS, in-order to provide a more solid empirical basis for
monitoring the national health situation and trends. The first and primary assumption of
this study is that all data provided for use in this study were accurate and reliable.
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The second assumption of this proposed study is that undocumented information
on the health center log reflects incomplete laboratory work. It is not clear if the patient
refused to submit sputum specimen or employees did not give adequate specimen
collection instruction to the patient. It may be the patient could not produce sputum
specimen. It is not clear if there was no designated area for the patient to collect the
specimen. The WHO (2017c) affirmed that the global health estimates represent the best
estimate by the WHO based on the evidence available to it.
Scope and Delimitations
The study was based on secondary data obtained from a community health center
in Addis Ababa, one of the largest cities in Ethiopia. Addis Ababa is an urban city with
adequate roads, transportation system, and has an accessible healthcare system.
Therefore, the city is not representative of most towns in Ethiopia.
One limitation of the study involves obtaining reliable data. Most data received
from local areas are estimates. Therefore, many international agencies, including the
WHO confirmed that available data are at best an estimate. Therefore, another limitation
is an incomplete result documentation process. The secondary data from the community
health center TB laboratory in Addis Ababa may reflect gaps in the specimen collection
and documentation of laboratory results.
Summary and Conclusion
Clinical laboratories are an integral part of a healthcare system. Laboratories play
a significant role in the diagnosis of a disease. The need to standardize laboratory
procedures across continents is vital. Health care-seeking behavior of the patient can
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delay diagnosis and treatment. However, once the patient arrives at the laboratory,
patients must receive full service. A failure to give full laboratory service is a lost
opportunity to diagnose and treat a patient.
The proposed study can provide an evaluation of the day-to-day activities of a
community health TB laboratory revealing the success and the challenges faced even
with the availability of high-technology instruments, like the Gene Xpert MDR-RIF-R
PCR assay.
It is considered vital to building on what a laboratory can achieve using current
procedures before moving into the use of instruments that require technical assistance.
Assessing, understanding, and revising existing procedures will require direct
participation from the local laboratory management group with the support of
international health agencies. The study will also recommend ways to improve the
current processes. The suggested procedures will build on what Ethiopia already
achieved and suggest optimal laboratory excellence to detect TB infections.
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Section 2: Research Design and Data Collection
Introduction
This study involves the evaluation of the collection and analysis of specimens
once the patient arrives in laboratory to complete and release TB test results for
laboratory technicians. The study examined and reported proper documentation of each
step during the laboratory process. The design choice advances the importance of
attention to details at each step of the laboratory process.
There are many laboratory processes and procedures to diagnose TB. TB may be
present in sputum, gastric lavage fluids, cerebrospinal fluid, urine, and a variety of
tissues. One procedure that is widely used is the AFB microscopic test. The purpose of
AFB microscopy is to detect AFB through microscopic examination of clinical
specimens. The light microscopy of ZN staining is prepared directly from sputum
specimens. The method is a widely used test for diagnosis of TB in resource-limited
settings.
The laboratory test starts with collecting sputum samples, followed by staining
and microscopic analysis to determine the absence or presence of AFB organisms. The
Xpert MTB/RIF PCR assay was recommended by the WHO in 2015 to be used as an
initial diagnosis for all people suspected to have pulmonary TB. To understand the
challenges faced by a health center in Addis Ababa, Ethiopia this study examined TB
laboratory procedures at one of the TB laboratories in the area.
The variables under study are the number of specimens collected, TB microscopic
test results, and TB and MDR-TB test results using the Gene Xpert instrument, as
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indicated in laboratory records. Data records are identified numerically as 1 through 160
participants.
Research Design and Rationale
The goal of the study was to investigate the potential challenges of TB
laboratories. The study applied the descriptive quantitative research design to assess
incomplete laboratory steps and test results based on a sample size of 160 laboratory
records from between August 2015 and December 2016. Laboratory records involved
numerical identifiers to itemize variables. The study analyzed secondary data obtained
from a community health center TB laboratory in Addis Ababa to perform descriptive
statistics for the collection of sputum specimen from TB-suspected patients, tresults ZN
microscopic tests, and the Gene Xpert instrument to detect MDR- TB. Since this study
used secondary data and there were no inferential research questions, the descriptive
quantitative design was most appropriate.
Methodology
The study objective was to determine adherence to standardized TB laboratory
procedures, using SPSS descriptive analysis and frequencies, which includes frequency
analysis for variables, number of specimens collected from TB-suspected patients,
sputum smear TB microscopy test results, and MDR-TB testing results using the Gene
Xpert instrument as indicated in laboratory records. Data records were identified
numerically.
The dataset was identified using numerical numbers with a sample size of
approximately 160 suspected TB patients from August 2015 to December 2016. Due to
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the fact that all data were included in the statistical analysis and there were no inferential
statistics, effect size and statistical power cannot be calculated.
Descriptive statistics and frequency table options allow the analysis of each coded
step to calculate frequency and a corresponding graph to visually represent how the
laboratory adhered to TB processing and resulting procedures set by the WHO.
Descriptive statistics include the number of processes that were resulted, not documented,
flagged as errors, or showed invalid results (error, invalid, undocumented, specimen not
collected) as part of the study. More specifically, the percentage of valid/documented
results when performing the ZN stain test and MDR-TB test for each suspected TB
patient was evaluated to see if they met WHO criteria; 5-15% error/undocumented results
are acceptable (WHO, 2015a). For failed laboratory steps, the study will make a
recommendation for improvement.
The research questions for this study are:
RQ1: During the period between August 1, 2015 and December 31, 2016 at a
community health center TB laboratory in Addis Ababa, what was the number of sputum
samples for detection of mycobacterium tuberculosis for suspected TB patients?
RQ2: Between August 1, 2015 and December 31, 2016 at a community health
center TB laboratory in Addis Ababa, what was the percentage of valid/documented
results when performing the laboratory ZN stain test for suspected TB patients?
RQ3: During the period between August 1, 2015 and December 31, 2016 at a
community health center TB laboratory in Addis Ababa, what was the percentage of
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valid/documented results when performing laboratory MDR-TB tests for suspected TB
patients?
Data Analysis
Variables and codes under study are displayed in Table 2. More specifically,
Table 2 includes information regarding the number of specimens collected, TB
microscopic test results, and TB and MDR-TB test results using the Gene Xpert
instrument, as indicated in laboratory records. All variables are categorical; therefore,
descriptive statistics include frequency percentages for each code per variable.
Additionally, for ZN and MDR-TB tests, a ratio of valid results was reported (number of
valid documented cases/all cases). All analyses were conducted using SPSS v. 24.
The laboratory is required to collect three sputum samples from each TBsuspected patient. The laboratory is also required to perform ZN staining for each
sputum and record microscopic results for each sputum sample. In addition, the
laboratory is also required to perform MDR-TB test using the Gene Xpert PCR
instrument for each MDR-TB suspected patients. Collecting three sputum samples and
performing ZN stains for each sputum sample and microscopic reading to obtain and
document three ZN stain results for each TB patient is required. In addition, Gene Xpert
PCR test results are required for all MDR-TB suspected patients.

The study assessed the percentage of failed test. For example, if no test result is
documented, if invalid test result documented, and error test result is documented. The
study also assessed if, corrective action process is in place to correct failure of laboratory

28
test. The study was limited to assessing the performance of the laboratory only. The study
does not assess or confirm patient diagnosis or treatment.
Table 2
Study Variables and Codes
Variables

Codes

Number of sputum
specimen collected from
each TB infection
suspected patient

01234-

None
1
2
3
Not documented

ZN stain sputum
microscopic test result

12345-

Negative
1-9 +
10-99 ++
>= 100 +++
Not Documented

MTB/RIF Assay results
using the Xpert PCR
instrument

0123-

TB Detected
TB Not Detected
TB Detected RIF Detected
TB Detected RIF Not
Detected
4- Instrument Error/invalid
5- Not documented

Threats to Validity
A secondary analysis examines data that were primarily collected for some
purpose other than the research studies. Secondary data will expedite and strengthen this
proposed research study. Secondary data will support the doctoral research as the data
will help develop, answer, and elaborate upon the research question. Result of a research
study is vital to the degree that it can be interpreted accurately and confidently. Accurate
and confident interpretation of a result is at the center of validity discussion. In this study,
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I analyzed the frequencies of events to establish a high occurrence of disagreeable
laboratory events that might affect patient health outcomes. The study result was valid
since it reflects the rate of laboratory results obtained and the frequency of undocumented
result and failed results. The study does not calculate associations between variables, and
thus no internal validity threats exist. Additionally, I do not generalize the results of the
study to other populations, since they are useful to evaluate TB data collection and
analysis procedures only in Ethiopia. The only threat to this study can be potential issues
with the secondary data, such as missing cases or incomplete data and I worked with the
health center to address these issues as much as I could.
Ethical Procedures
Research should always be conducted ethically. It is important to get the required
permission when a research study involves human subjects and accessing patient health
information. This study was conducted using a secondary data set without any direct
interaction with patients, and no patient identifiers are used. The laboratory record used
numerical identifiers to itemize variables. I received approval by Addis Ababa University
Research Review Board (AAURRB) to receive and analyze the data. Additionally,
Walden IRB also approved this study (#12-17-19-0466211). All data will be stored in
password-secured files in my computer for at least 5 years per Walden policy.
Summary
Clinical laboratories are an integral part of a healthcare system. Laboratories play
a significant role in the diagnosis of a disease. The need to standardize laboratory
procedures across continents is vital. Health care-seeking behavior of the patient can
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delay diagnosis and treatment. However, once the patient arrives at the laboratory,
patients must receive full service. A failure to give full laboratory service is a lost
opportunity to diagnose and treat a patient. The study objective is to determine adherence
to standardized TB laboratory procedure using SPSS which includes frequency analysis
for variables, number of specimens collected from each TB suspected patient, sputum
smear TB microscopy test results, and MDR-TB testing results using the Gene Xpert
instrument as indicated in laboratory records.
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Section 3: Presentation of the Results and Findings
Introduction
The study used a quantitative descriptive design to determine levels of
adherence in a community health center TB laboratory in Addis Ababa, Ethiopia to
standardize TB laboratory procedures. The study involved sputum samples from each
suspected TB patient, and the valid/documented results of laboratory ZN stain test and
MDR-TB test for each suspected TB patient at the center under study.
RQ1: During the period between August 1, 2015 and December 31, 2016 at a
community health center TB laboratory in Addis Ababa, what was the number of sputum
samples for detection of mycobacterium tuberculosis for suspected TB patients?
RQ2: Between August 1, 2015 and December 31, 2016 at a community health
center TB laboratory in Addis Ababa, what was the percentage of valid/documented
results when performing the laboratory ZN stain test for suspected TB patients?
RQ3: During the period between August 1, 2015 and December 31, 2016 at a
community health center TB laboratory in Addis Ababa, what was the percentage of
valid/documented results when performing laboratory MDR-TB tests for suspected TB
patients?
Data Collection of Secondary Data Set
The study used secondary data collected by the TB laboratory from August 1,
2015 to December 31, 2016. Patients who come to this laboratory are suspected of having
TB infections, and they are referred by primary care physicians to submit sputum samples
for laboratory examination. Typically, urban cities in Ethiopia have access to
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transportation; therefore, patients in Addis Ababa have the option of using a city train or
taxi. The TB laboratory is a government-run laboratory, and patients are charged a
reduced fee for laboratory services compared to private laboratories.
Results
The variables under study are the number of specimens collected, TB microscopic
test results, and TB and MDR-TB test results using the Gene Xpert instrument, as
indicated in laboratory records. Data records were identified numerically as 1 through
162.
Descriptive statistics data analysis was performed using SPSS version 25. All
variables are categorical and reported as frequencies (%).
In Table 3, 1.2% of the sample was RMP detected and 2.5% was RMP resistant
indeterminate. It is indicated that in 86.4% of the sample, tests were not performed, and
of 13.6% test that was performed, 2.5% were recorded as errors.
Table 3
Frequency Table for MTB-RIF Assay Xpert Instrument

TB not detected
TB detected RMP resistant
detected
TB detected RMP resistant not
detected
Error
Not performed
Total

Frequency

Percent

12
2

7.4
1.2

Valid
Percent
7.4
1.2

4

2.5

2.5

4
140
162

2.5
86.4
100.0

2.5
86.4
100.0

For 4.4% and 21.5% of participants’ two sputum samples and one sputum sample were
submitted, respectively. The optimal number of three samples was submitted only for the
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48.1% of the study population and 25.9% of patients for whom no sputum samples were
provided.
Table 4
Sputum Samples Collected Per Patient

Missing
Total

0
1
2
3
Total
System

Frequency
41
34
7
76
158
4
162

Percent
25.3
21.0
4.3
46.9
97.5
2.5
100.0

Valid
Percent
25.9
21.5
4.4
48.1
100.0

In addition, Tables 5, 6 ,and 7 show that for samples 1, 2, and 3there were results only for
72.2%, 51.2%, and 47.5% of study participants, respectively, and for the rest no
evaluation was peformed.
Table 5
Frequency Table: Sample 1

no +
+
++
+++
Not
performed
Total

Frequency

Percent

106
1
6
4
45

65.4
.6
3.7
2.5
27.8

Valid
Percent
65.4
.6
3.7
2.5
27.8

162

100.0

100.0
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Table 6
Frequency Table: Sample 2

no +
+
+++
Not
performed
Total

Frequency
75
2
6
79

Percent
46.3
1.2
3.7
48.8

Valid
Percent
46.3
1.2
3.7
48.8

162

100.0

100.0

Frequency
69
4
4
85

Percent
42.6
2.5
2.5
52.5

Valid
Percent
42.6
2.5
2.5
52.5

162

100.0

100.0

Table 7
Frequency Table: Sample 3

no +
++
+++
Not
performed
Total

Summary
For RQ1, where the number of sputum specimens collected was evaluated for
each suspected TB patient, an optimal number of three samples was submitted only for
48.1% of the study population and no sputum were provided for 25.9% of patients.
For RQ2, where the percentage of valid/documented results for samples 1, 2, and,
3 when performing the laboratory ZN stain test for each suspected TB patient was
evaluated there were results only for 72.2%, 51.2%, and 47.5% of study participants,
respectively, and for the rest no evaluation was peformed.
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For RQ3, where the percentage of valid/documented results when performing the
MDR-TB test for each suspected TB patient was evaluated, it was indicated that in 86.4%
of the sample, the test was not not performed and among 13.6% of that population, 2.5%
was recorded as having errors. For all research questions, WHO criteria for 5-15%
error/undocumented results were not met.
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Section 4: Application to Professional Practice and Implications for Social Change
Introduction and Key Findings
The principal purpose of this study was to determine level of adherence to
standardized TB laboratory procedures by calculating and reporting the number of
sputum samples from each suspected TB patient, as well as valid and documented results
of ZN stain tests and MDR-TB tests for each suspected TB patient at a community health
center TB laboratory in Addis Ababa, Ethiopia. In this section, I will provide the key
results for each research question and how these results compare to WHO criteria.
For RQ1, where the number of sputum specimens collected was evaluated for
each suspected TB patient, the optimal number of three samples was submitted only for
48.1% of the study population, and no sputum was provided for 25.9% of the patients.
For RQ2, where the percentage of valid and documented results for samples 1, 2, and, 3
when performing the laboratory ZN stain tests for each suspected TB patient was
assessed, there were results only for 72.2%, 51.2%, and 47.5% of study participants,
respectively, and for the rest no evaluation was performed. Therefore, the WHO criteria
of 5-15% error/undocumented results were not met. In exploring RQ3, for which the
percentage of valid and documented results when performing the MTB-RIF-TB test for
each suspected TB patient was evaluated, 86.4% of the sample MTB-RIF-TB test was not
performed; this is significantly high compared to WHO criteria of 5-15% for error and
undocumented results.
Second, I will compare these data to similar data reported by the WHO and other
countries to ascertain how Ethiopia stands regarding standardized procedures and
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discussed potential deviations from these standards. In this section, I will discuss the
results of the study compared to the WHO and Sub-Saharan African countries with
similar demographics. Second, I will discuss these results based on the theoretical
framework I suggested in Section 1. In this section, I will also discuss interpretations of
the study results in relation to the theoretical framework. I will also discuss and compare
TB laboratory studies and results from other Sub-Saharan countries.
Interpretation of the Results
Onyebujoh et al. (2017) said that Africa is home to 26% of estimated incidences
of all TB cases (2.7 million) and TB death rates in Africa are three times greater than the
global average. Summer et al. (2019) said it is sometimes assumed that the only
constraint is the health sector budget; however, even if funding is available, it may take
time to allocate necessary staffing and infrastructure to deliver TB services. Improving
equitable access to TB diagnosis and treatment remains the most pressing need for
Africa, where laboratory services play a pivotal role (Onyebujoh et al., 2017).
Since 2011, investments in molecular TB diagnostics have multiplied, as reflected
by the deployment of an increasing number of Cepheid GeneXpert systems across Africa.
However, these efforts were not being translated into an increased diagnosis of TB cases
or increased laboratory confirmations of cases that were notified (Onyebujoh et al.,
2017).
Onyebujoh et al. (2017) said that the numbers of laboratories providing TB
diagnostic services using smear microscopy and GeneXpert have gradually increased.
However, the overall number of new laboratory-confirmed tuberculosis cases has not
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increased. As a more sensitive and accurate molecular diagnostic tool, the potential of
GeneXpert technology to improve the diagnosis of tuberculosis/HIV cases has yet to be
fully realized since it was introduced in 2011.
Summer et al. (2019) said in South Africa, mathematical models are increasingly
being used to compare strategies for TB control without detailed information regarding
implementation. Decision-makers need information about local resources, infrastructure,
culture, practices, needs, and wants of the local area.
For RQ1, three samples were submitted only for 48.1% of the study population,
and for 25.9% of the patients, no sputum samples were provided. In some cultures,
people may need a covered area or a room to collect sputum samples, and in many
resource-limited countries, restrooms are not always available. Testing three samples can
increase the sensitivity of TB diagnosis to 90.2% (Sujata, 2014).
Dzodanu et al. (2019) said that in many developing countries, the diagnosis of TB
is mostly based on the ZN staining technique. The ZN method, however, is reported to
be low and variable, ranging from 20 to 80%, often depending on the diligence with
which specimens are collected, smears are made, and stained smears are examined. The
WHO guideline is to collect three specimens per patient. Parsons et al. (2011) said
examination of only two smears in place of three could ease the workload of laboratories,
decrease time for diagnosis and initiation of treatment, and decrease the number of
patients dropping out of the diagnostic pathway by one third, particularly in countries
with a high microscopy workload. In addition, patients will spend less time at the
diagnostic facility. However, reduction of the number of specimens examined for the
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screening of TB patients from three to two specimens should be recommended only in
settings with a well-established laboratory network and fully-functional EQA program for
smear microscopy, including onsite evaluation and followup training for problem
laboratories. Also, reducing the number of sputum specimens collected may leave a
significant number of cases undetected, especially if it becomes the only means of
diagnosis.
RQ2 involves the percentage of valid and documented results when performing
laboratory ZN stain tests for each suspected TB patient. My study revealed that the
results for samples 1, 2, and, 3 when performing the laboratory ZN stain test for each
suspected TB patient, were only 72.2%, 51.2%, and 47.5% of study participants,
respectively, and for the rest no evaluation was performed. This negative result highlights
the importance of a reliable support system that includes training. Haile et al. (2014) said
that there is a country-wide problem regarding the purchasing of reagents, laboratory
consumables, and quality control materials. Merton’s theory of unintended consequences
of social action is useful to investigate how decision-makers decide what is beneficial for
a local area. Solinas-Saunders and Stacer (2015) said that many factors are intertwined,
and the choices are formed within a social context constrained by time and space. One’s
action rationality is a function of their interpretation of reality in the context of a social
system (Merton, 1936). In 22 high burden countries (of which Ethiopia is one) with 80%
of tuberculosis cases worldwide, a systematic review of 37 eligible studies of serial
sputum specimen results indicated that almost 85.8% of TB cases were detected with the
first sputum specimen. With the second sputum specimen, the average incremental yield
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was 11.9%, while the incremental yield of the third specimen, when the first two
specimens were negative, was 3.1%.
RQ3 regarding the Gene-Xpert instrument test indicated that in 86.4% of the
sample, the test was not performed, and of 13.6 % test that was completed, 2.5% was
recorded as an error. The Xpert MTB/RIF PCR assay was recommended by the WHO in
2015 to be used as an initial diagnosis for all people suspected to have pulmonary TB).
Xpert MTB/RIF is an automated, cartridge-based nucleic amplification assay for the
simultaneous detection of TB and rifampicin resistance directly from sputum in less than
two hours (WHO, 2017a). However, the presence of a reliable support system that
includes training, infrastructure, and timely technical backing is highly recommended to
make the PCR testing worthwhile. Summer et al. (2019) discussed the critical impact and
cost-effectiveness of TB case detection, where sometimes it is assumed that the only
constraint is the health sector budget. However, even if funding is available, it may take
time to allocate the necessary staffing and the infrastructure to deliver TB services. Rice
(2017) stated that the detection of (MTBC and RIF resistance has been well documented
in low-resource settings with high TB-incidence. However, few studies have assessed its
accuracy in low TB incidence settings with high resources. A retrospective study
evaluated the performance of Xpert MTB/RIF using clinical sputum specimens routinely
collected from suspect pulmonary TB patients in San Diego County, California. Xpert
MTB/RIF results were compared to acid-fast bacilli (AFB) smear microscopy,
mycobacterial culture, and phenotypic drug susceptibility testing (DST) (Rice 2017). In
this study, the Xpert MTB/RIF assay was performed following CDC recommendations
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for PCR testing to be performed on at least one respiratory specimen, from each patient
with signs and symptoms of pulmonary TB. In general, the Xpert MTB/RIF assay was
used to test the first AFB smear-positive specimen collected from each patient, as well as
AFB smear-negative specimens per clinician request in patients with a high suspicion of
pulmonary TB. Of 751 sputum specimens, 134 (17.8%) were MTBC culture-positive and
2 (1.5%) were multidrug-resistant (MDR) (Rice 2017).
Xpert MTB/RIF detected 35 of 47 smear-negative culture-positive specimens
and excluded 124 of 137 smear-positive culture-negative specimens. Xpert MTB/RIF
also correctly excluded 99.2% (121/122) of nontuberculous mycobacteria (NTM)
specimens. It also eliminated all 33 NTM false-positives by smear microscopy. Xpert
MTB/RIF sensitivity and specificity for the detection of RIF resistance were 100% (2/2)
and 98.3% (116/118), respectively (Rice, 2017). The success of such scenario underscores the availability of an in-built infrastructure in developed countries, that might be
taken for granted while implementing high-tech instruments in developing countries.
More often the lack of funding for such project might sufficiently been addressed
however, it might not only be a lack of funding, Summer et al. (2019) discuss the critical
impact and cost-effectiveness of TB case detection, where sometimes it is assumed that
the only constraint is the health sector budget. However, even if funding is available, it
may take time to allocate the necessary staffing and the infrastructure to deliver TB
services.
The study by Ardizzoni et al. (2015) describes the performance of Xpert and
critical lessons learned during two years of implementation under routine conditions in 33
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projects located in 18 countries supported by Médecins Sans Frontières across varied
geographic, epidemiological and clinical settings. Routine laboratory data were
collected, using laboratory registers. Qualitative data such as logistics, human resources,
and methodology approval were collected using a questionnaire. First, Xpert was used as
the initial test, with microscopy in parallel, for all possible TB cases. Second Xpert was
used for patients at risk of MDR-TB, or with HIV associated TB, or presumptive
pediatric TB; and the third Xpert was used if test is the initial test for high-risk patients as
an add-on test to microscopy. The average MTB detection rate was 18.5%, 22.3%, and
11.6% for the above three different tests, respectively.
The results microscopic tests in parallel with Xpert as an add-on test to
microscopy test increased laboratory TB confirmation by 49.7%. The major drawback of
the test was the high rate of inconclusive results, which correlated with factors such as
defective modules, cartridge version (G3 vs. G4), and staff experience. Operational and
logistical hurdles included infrastructure renovation, basic computer training, regular
instrument troubleshooting, and maintenance, all of which required substantial and
continuous support (Ardizzoni et al. 2015).
Considering the results from these studies, we are confident the challenges faced
in low-resource settings with high TB-incidence, needs attention to address the lack of
comprehensive technical assistance, including the formulation of policies, infrastructure
issues and plans to address operational issues.
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Study Results and Theoretical Framework
It is essential to investigate that diagnostic tools are accurate and supported by
available resources in the local area to have a direct impact on case prevention and saving
a life. Merton (1936) explains this situation that decision-makers act rationally by
selecting a means based on the available evidence, and yet the goal may not be attained.
Merton (1936) further explains that the most obvious limitation to correct anticipation of
consequences of an action is the existing state of experience. Therefore, limited
knowledge can be the sole barrier to correctly anticipating a future outcome. SolinasSaunders and Stacer (2015) said that some health interventions carry unintended
consequences that are unpredictable while some are seen and prevented. For example, if
we apply Merton’s theory of compassion for those marginalized (poverty-stricken TB
patients), it often motivates purposive social action. Based on Merton’s theory of
unintended consequence of purposive action, the demand for social engagement is
pressing, as is the need for immediate results.
According to Merton’s theory, available knowledge is another way in which
decision-makers’ conclusions are restrained. When trying to decide what type of
treatment, diagnostic procedure, or medical equipment is appropriate, decision-makers
need information about local resources, culture, practices, needs, and wants of the local
area. They lack knowledge, or their ability to translate knowledge into empirical data
with the need to obtain immediate results limits the ability to predict the outcome with
certainty (Merton, 1936).
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The issue of the country’s limited infrastructure, insufficient technical training,
and limited troubleshooting abilities of laboratorians need to be considered in full before
making any decisions. It is also crucial to investigate the availability of infrastructure
capabilities, training, and technical support. These activities should be determined,
sustained, and be managed by the country's local health department managers with the
total backing by decision-makers and international agencies.
Xpert MTB/RIF Studies in Sub-Saharan Africa
In 2010, the WHO endorsed the use of Xpert MTB/RIF, a rapid diagnostic assay
that can identify Mycobacterium tuberculosis and resistance to rifampicin. WHO
recommendation included the use of Xpert MTB/RIF as a primary diagnostic test for
adults with suspected drug-resistant TB, for children and adults with suspected TB in
settings with high HIV prevalence, and the detection of extra-pulmonary TB. Resources
permitting, Xpert may also be used as an initial diagnostic test for all patients with
suspected TB or as a follow-on test to microscopy for adults with smear-negative results
(WHO, 2011a).
In 2014, 4.8 million Gene Xpert cartridges were acquired in the public sector in
116 countries of the 145 countries eligible for concessional pricing, and Ethiopia was one
of these countries (Umubyeyi et al. 2016). Its availability at lower-level health facilities
like Community health TB laboratory is an added benefit to improving access to testing.
However, Umubyeyi et al. (2016), states that studies and models have presented potential
uses and impacts of the test. Still, few results have been published on the implementation
program of Xpert instruments at a large scale.
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Umubyeyi et al. (2016) state that the implementation of Xpert was conducted in
five Sub-Saharan African countries. It was done in collaboration with the US Agency for
International Development, the African Society of Laboratory Medicine, the WHO and
the Global Fund to Fight AIDS, Tuberculosis, and Malaria in five Sub-Saharan African
countries, which are, the Republic of Congo, Eritrea, Ethiopia, Ghana, and Kenya.
The study results from two countries illustrate the direct impact of these
interventions: in Kenya, 8221 Xpert tests were conducted in 2015, of which 1830
(22.3%) were positive for M. tuberculosis, and 81 (4.4%) were rifampin resistant. In
Ethiopia, evaluation after the first year of implementation (July 2013–December 2014)
showed a 22% increase in the number of drug-resistant TB cases detected, while total TB
cases detected rose from 58 802 to 63 168 (7.5%). The contribution of Xpert to TB case
detection was 2% (source: Ethiopia National TB Program, 2015). Regarding the impact
of Xpert on patient care, the study state that there are no significant or systematic
improvements linking diagnosed patients to treatment. Generally, empirical treatment
remained the rule, even with the availability of additional information about drug
resistance, for example, with Xpert MTB/RIF testing. Overall, the utilization of the Xpert
machines was at 15% of full capacity, representing a missed opportunity to diagnose
potential TB and drug-resistant TB cases due to poor referral and transport systems.
Umubyeyi et al. (2016) state to achieve the maximum impact from innovative
diagnostics systems, like Xpert, countries should improve the quality of health care,
commit the resources needed, and implement a strategic plan for laboratory services and
involve laboratory experts to guide implementation. The research study at the
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Community Health Center TB Laboratory showed a need for attention to details that can
come from a commitment and involvement of the local laboratory experts with
knowledge and experience.
Social Change
Due to limited access to a well-developed health insurance system, about 80 % of
private health expenditure in Ethiopia is via Out of Pocket Payments (OOPs,) and private
insurance institutions cover only 1.5 % of private healthcare expenditure. Providing
healthcare to individuals working informally or who live in rural areas is a significant
challenge in developing countries (Badacho et al., 2016).
Considering the challenges faced by government health facilities and by the
patient in developing countries, the proposed study at the Community Health Center TB
laboratory will evaluate TB laboratory procedures and share its findings. The laboratories
must provide detailed and complete laboratory test results once the patient managed to
travel to the Community Health Center and paid out-of-pocket charges. The situation
might erode patient’s confidence and affect their compliance of submitting required
samples for laboratory tests. Undiagnosed infection creates a cycle of disease leaving the
country’s population vulnerable by spreading the infection to family and community
members.
TB laboratory processes need to be structured, systematized, and entirely led by
local laboratory managers and Directors, supported by government officials and
international agencies, to have a sustained impact. Empowering local professionals and
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laboratory managers to be engaged and make sound decisions based on local resources is
a positive social change.
Limitation of the Study
Global health estimates represent the best estimate by WHO based on the
evidence available to it. Clinical laboratories are part and parcel of the healthcare
services; in that respect, the proposed study results will be shared with the FDRE MOH.
The study result can be extrapolated to represent other urban cities in Ethiopia to give
insights to TB laboratory professionals and managers. However, this study population is
not representative of all regions in Ethiopia, especially the rural areas.
Recommendations
It is vital to evaluate what a laboratory can achieve using the current procedures
before starting to use an instrument that requires high technical assistance. Assessing,
understanding, and revising existing procedures will require direct participation from the
local laboratory management group with the support of international health agencies.
The study recommends a direct and step by step participation of local laboratory
professionals and laboratory managers to decide which laboratory instrument or
procedure will work best to enable them to complete and obtain a valid result for each
laboratory test. The study also recommends that local laboratory professionals and
laboratory managers should plan a test validation process using a previously confirmed
positive and negative patient samples or a positive and a negative quality control sample
to validate the testing process and the new instrument. Once validation is successful, the
local laboratory professionals and laboratory managers should develop an
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implementation plan. Making sure that infrastructures, including electricity, water,
consumables, training of all laboratory technicians, including all trouble-shooting
training, are completed before starting the TB testing. It is a widespread problem that
instruments remain inoperative for an extended period waiting for a technical assistant
from medical device companies that are not always nearby (Umubyeyi et al., 2016).
For failed laboratory steps, the study recommends clear documentation of why a
laboratory process failed. The research also suggests that the laboratory should document
what steps were taken to correct any failure of the laboratory process. Clinical
laboratories play a significant role in identifying and treatment of a specific disease.
However, throughout this research study, it is cited that the infrastructure, level of
support for surveillance, research, and training in health care fields in Ethiopia is
minimal. However, based on this study’s results, it is suggested that the laboratory
professionals who are managing the TB laboratory or those who are overseeing the
laboratory procedures need to be fully engaged to make sure that TB laboratory tests are
performed and obtain a valid test result. WHO allows 5-15% error or invalid results. The
study recommends that the ZN microscopic test with no results, error/invalid test result
and less than three sputum samples should have:
•

Documentation to explain why the test failed

•

Documentation for corrective action. One example of a corrective action could be
repeating the test and releasing the test result the same day.

•

Documentation of reason for less than three sputum samples collection and a
corrective action.
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I also recommend future studies to analyze the reason for the failure of a process (error,
invalid, undocumented, not collected) as part of the study.
Implications for Professional Practice and Social Change
The study captures the day to day activities of a community health TB laboratory
revealing the success, and the challenges faced when implementing the use of high-tech
instruments like the Gene Xpert MDR RIF-R PCR Assay. It is vital to evaluate resources
in terms of infrastructure, technical, and material resources before implementing a highly
specialized process that requires immediate attention and support. Assessing,
understanding, and evaluating existing laboratory procedures is only a start. The study
result will be disseminated including to FDREMOH.
The answer to Ethiopia’s TB disease complexity should come from Ethiopians
leadership of scientific research. This can only happen with full engagement of
laboratorians and researchers in understanding the local laboratory concerns and other
related problems, no matter how small and redressing it from their point of view,
ensuring the sustainability of resources needed. Zumla et al. (2015) ascertained that the
more African scientists and researchers take on the leadership role, it has become
imperative that other funding agencies consider aligning their research and capacity
building investments in Africa to have a cooperative and growing effect. It is only
through the empowerment of the next generation of African scientific leaders who will
conduct the highest level of research that Africa will be able to generate local solutions to
local health issues.
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Umubyeyi et al. (2016) stated that Implementation of Xpert MTB/RIF, new
technology, requires better country preparedness. Training, policies, and plans to address
operational issues, comprehensive technical assistance, significant laboratory
infrastructure improvement, and finally, the development of a TB laboratory strategic
plan from the local government official and laboratory managers. It should include a
proposal to the roll-out of Xpert Gene Xpert MDR RIF-R PCR Assay and coordinate
support from donors and partners.
Umubyeyi et al. (2016) continue to discuss that countries with low resources
have suffered from a lack of comprehensive technical assistance, including the
formulation of policies and plans to address operational issues.
In Ethiopia, to fulfil these requirements, countries must coordinate the support of
donors and partners and propose a budget and plan that covers technical assistance needs,
the development of a TB laboratory strategic plan, including the roll-out of Xpert and the
coordination of support from donors and partners.
I will analyze and share the outcome of the study to recommend an adjustment to
the current processes and procedures to build on what is already achieved to move
forward and empower local decision-makers to work towards sustained laboratory
excellence based on available resources. Therefore, the potential impact of this study will
reflect a positive social change at the individual, organizational, and government levels.
Conclusion
The study will contribute to changing the way Ethiopian laboratory technicians
and managers are empowered to enable them to address the local challenges without too
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much reliance on outside prompting, which will constitute a positive social change. TB
laboratory processes that are structured, systematized, and entirely led by local laboratory
managers and directors, supported by government officials and international agencies,
will have a sustained impact. Empowering local professionals and laboratory managers to
be engaged and make sound decisions based on local resources is a positive social
change.
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